Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.114811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Samuel C Scharffenberger und 18 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Laboratory Medicine and Pathology, Univ…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Receptors, Antigen, B-Cell, Antibodies, Anti-Idiotypic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Gates Foundation.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) causes lower respiratory tract infections with significant morbidity and mortality at the extremes of age. Vaccines based on the viral fusion protein are approved for adults over 60, but infant protection relies on passive immunity via antibody transfer or maternal vaccination. An infant vaccine that rapidly elicits protective antibodies would fulfill a critical unmet need. Antibodies arising from the VH3-21/VL1-40 gene pairing can neutralize RSV without the need for affinity maturation, making them attractive to target through vaccination. Here, we develop an anti-idiotypic monoclonal antibody (ai-mAb) immunogen that is specific for unmutated VH3-21/VL1-40 B cell receptors (BCRs). The ai-mAb efficiently engages B cells with bona fide target BCRs and does not activate off-target non-neutralizing B cells, unlike recombinant pre-fusion (preF) protein used in current RSV vaccines. These results establish proof of concept for using an ai-mAb-derived vaccine to target B cells hardwired to produce RSV-neutralizing antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Department of Global Health, University of Washington, Seattle, WA 98195, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Global Health, University of Washington, Seattle, WA 98195, USA.
- Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA 19104, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Gates Foundation
- NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
- National Institutes of Health
- Argonne National Laboratory
Zitieren
APA
Scharffenberger, S. C., Wan, Y. H., Homad, L. J., Kher, G., Haynes, A. M., Poudel, B., Sinha, I. R., Aldridge, N., Pai, A., Bibby, M., Chhan, C. B., Davis, A. R., Moodie, Z., Palacio, M. B., Escolano, A., McElrath, M. J., Boonyaratanakornkit, J., Pancera, M., & McGuire, A. T. (2024). Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114811
Vancouver
Scharffenberger SC, Wan YH, Homad LJ, Kher G, Haynes AM, Poudel B, et al. Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114811
BibTeX
@article{Scharffenberger2024,
author = {Scharffenberger, Samuel C and Wan, Yu-Hsin and Homad, Leah J and Kher, Gargi and Haynes, Austin M and Poudel, Bibhav and Sinha, Irika R and Aldridge, Nicholas and Pai, Ayana and Bibby, Madeleine and Chhan, Crystal B and Davis, Amelia R and Moodie, Zoe and Palacio, Maria Belen and Escolano, Amelia and McElrath, M Juliana and Boonyaratanakornkit, Jim and Pancera, Marie and McGuire, Andrew T},
title = {Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.114811}
}
EUVIMED